Davis R M Inc. Cuts Position in STERIS plc (NYSE:STE)

Davis R M Inc. trimmed its position in STERIS plc (NYSE:STE - Free Report) by 8.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,066 shares of the medical equipment provider's stock after selling 3,552 shares during the period. Davis R M Inc.'s holdings in STERIS were worth $7,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new position in shares of STERIS in the third quarter valued at about $25,000. Human Investing LLC acquired a new stake in shares of STERIS in the fourth quarter worth $31,000. Anfield Capital Management LLC raised its holdings in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 91 shares during the last quarter. Central Pacific Bank Trust Division lifted its position in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 76 shares during the period. Finally, Manchester Capital Management LLC boosted its holdings in STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

Analyst Upgrades and Downgrades

STE has been the subject of a number of recent research reports. Stephens reiterated an "overweight" rating and set a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. JMP Securities reaffirmed a "market outperform" rating and set a $265.00 target price on shares of STERIS in a report on Thursday, February 6th. Finally, Piper Sandler boosted their price target on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $258.75.

Remove Ads

STERIS Price Performance

STERIS stock traded down $2.07 during trading on Thursday, reaching $222.39. The company had a trading volume of 419,169 shares, compared to its average volume of 528,583. The firm has a market capitalization of $21.85 billion, a PE ratio of 47.22 and a beta of 0.92. The firm's 50-day simple moving average is $218.71 and its 200 day simple moving average is $222.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. STERIS plc has a 1-year low of $197.82 and a 1-year high of $248.24.

STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, equities research analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.03%. STERIS's dividend payout ratio is currently 48.41%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.